495 Results

Phase III RANGE trial of Cyramza shows positive trend in advanced urothelial carcinoma.- Eli Lilly.

 Added 2 days ago

Eli Lilly announced additional results from its global, randomized, double-blind, placebo-controlled Phase III RANGE trial evaluating Cyramza (ramucirumab) in combination...

Rocapuldencel-T + sunitinib combination fails Phase III ADAPT trial to treat renal cell carcinoma.-Argos Therapeutics.

 Added 5 days ago

Argos Therapeutics, Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis precision...

FDA approves combination Opdivo + Yervoy to treat intermediate- and poor-risk advanced renal cell carcinoma.- BMS.

 Added 8 days ago

Bristol-Myers Squibb Company has announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was...

Inlyta fails Phase III trial as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy .- Pfizer

 Added 14 days ago

-Pfizer Inc. has announced that the independent Data Monitoring Committee for the Phase III ATLAS trial evaluating Inlyta (axitinib) as...

Recordati to market Cystagon in Europe for nephropathic cystinosis.- Mylan

 Added 15 days ago

Recordati announces the completion of an agreement with Mylan for the acquisition of the rights to Cystagon (cysteamine bitartrate), indicated...

Phase III trial data for Auryxia in iron deficiency anemia published in American Journal of Hematology.- Keryx Biopharmaceuticals.

 Added 20 days ago

Keryx Biopharmaceuticals announced the publication of a post-hoc analysis of Auryxia (ferric citrate) phase III trial data for iron deficiency...

FDA plans Advisory Committee Meeting for plazomicin for the treatment of complicated urinary tract infections .- Achaogen, Inc.

 Added 29 days ago

Achaogen, Inc. a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, announced that the Antimicrobial Drugs...

CHMP recommends approval for four week dosing schedule of Opdivo for advanced melanoma and renal cell carcinoma. BMS.

 Added 29 days ago

-Bristol-Myers Squibb Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has...

Load more